v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Information [Abstract]  
Segment Information
13.  Segment Information
 
We operate as a single operating segment, Ionis operations, focused on the research, development and commercialization of our RNA-targeted medicines to bring better futures to people with serious diseases. The CODM, our Chief Executive Officer, manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using consolidated net income or loss as the key measure of segment profit or loss. As such, results of our operations are reported on a consolidated basis for purposes of management and segment reporting.
 
Ionis operations derives its revenues from commercial and R&D revenue sources. Refer to Note 4, Revenues, for further details on our sources of revenue.
The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands):
 
 Three Months Ended Six Months Ended
 June 30, June 30,
  2026   2025   2026   2025 
Revenue$267,949  $452,049  $514,042  $583,660 
                
Less:               
Cost of sales 2,563   3,541   5,398   4,904 
Drug discovery 29,120   30,255   57,677   57,244 
Drug development 103,958   117,689   208,140   230,635 
Medical affairs 11,318   7,826   21,307   13,468 
Manufacturing and development chemistry 20,639   21,545   40,947   35,826 
R&D support 26,974   20,607   49,405   41,159 
Selling, general and administrative 130,075   81,081   262,012   148,061 
Other segment items (1) 57,948   45,954   76,330   75,750 
Consolidated net income (loss)$(114,646)  $123,551  $(207,174)  $(23,387) 
 
(1)  Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.